NEW ORGANIC SILICON COMPLEXES, AND APPLICATIONS

Abstract

The present invention relates to novel organic silicon complexes, as well as their applications.

Description

Title of the invention: NEW ORGANIC SILICON COMPLEXES, AND APPLICATIONS Field of the invention

[0001] The present invention relates to new organic silicon complexes, as well as their applications. State of the art

[0002] People are living longer all over the world. By 2030, one in six people worldwide will be 60 or older (WHO Bulletin “Aging and Health”, 1 Oct. 2024). One of the major challenges of the 21st century therefore remains health and the fight against aging, which some define, at least from a physiological point of view, as the product of the accumulation over time of a wide range of molecular and cellular damage, ultimately impairing the body's physical and intellectual capacities (Boismal F. et al., Médecine / Sciences, 2020, vol. 36, pp. 1163-72). However, among the multitude of studies initiated over decades by the scientific community (gerontologists, molecular biologists, immunologists, neuroscientists, etc.)To better understand the mechanisms of chronological aging in the human body and to develop ways to slow down or prevent its negative effects, it is well established in pathophysiology that one of the biomarkers of this general senescence is the measurement of the molecular aging of proteins (Jaisson S. et al., Médecine / Sciences, 2017, vol. 33, pp. 176–182). Indeed, throughout their time in the living cells of the body, this large class of biological macromolecules is cumulatively exposed to deleterious reactions that progressively contribute to the alteration of their structural and functional properties, thereby affecting the regulation of their molecular and cellular interactions.From a mechanistic point of view, it is also accepted that this deleterious reaction sequence involves, over time, various complex processes, largely grouped in the literature under the term "Non-Enzymatic Post-Translational Modifications (NEPTMs)" (Jaisson S. et al., Adv. Clin. Chem., 2018, vol. 84, pp. 1-38). In essence and in simple terms, these are unprogrammed but inevitable chemical reactions characterized by the unregulated, often irreversible, binding of simple metabolites to the amino acid residues (functional groups) of proteins. The most studied of the aforementioned MPTNEs affecting proteins are four in number (Gillery P. et al., Clin. Chem. Lab. Med., 2013, vol.92, pp.228-238). First, there is the oxidation reaction, with damage caused by the action. Reactive oxygen species (ROS), particularly oxygen free radicals, are involved in the formation of reactive metabolites on proteins. There are also non-enzymatic reactions known as carbonylation and carbamylation, which correspond respectively to the attachment of reactive carbonyl derivatives / species (RCCs) and isocyanic acid (source: urea) to the amino groups of these same proteins. Finally, there are the extensively studied non-enzymatic reactions of glycosylation and glycoxidation of proteins, the latter corresponding to the former but combined and accentuated in the presence of an oxidizing environment. These reactions consist of the condensation of reducing sugars, such as glucose or fructose, onto the N-terminal amino groups of certain protein, lipoprotein, or nucleoprotein constituents.When impacted in this way, the corresponding biomolecules (proteins, lipids, and nucleic acids) cross-link and then become irreversibly rigid with the accumulation of inter-fiber covalent cross-links, similar to the changes observed in glycosylated collagen fibers exposed to excess glucose during the in vitro development of an experimental model for monitoring diabetes mellitus (Kent MJC, Biochem. J., 1985, vol. 225, pp. 745–752). Furthermore, this is correlated with blood hyperglycemia, and it is emphasized that such non-enzymatic glycosylation of proteins, and its repercussions, do not have a purely endogenous origin in the body. The phenomenon is indeed likely to be amplified by an exogenous contribution, for example that of food, precisely through the excessive coloring and browning of proteins that our modern cuisine tends to give to foodstuffs under the effect of strong cooking.Therefore, this results in a "caramelization of proteins" (Defaye J. et al., L'Actualité Chimique, 2000, pp.24-27) which is nothing other than a MPTNE described above and which is likely to generate, after ingestion, when the degradation or excretion of the newly formed molecules during cooking is insufficient, a food pollution / nuisance (carcinogenicity, pro-oxidant and inflammatory biological activities) involved in the pathophysiology of the aging of the organism and the amplification of the complications of diabetes (Schlienger JL, Médecine des Maladies Métaboliques, 2022, vol.6, pp.567-572). Furthermore, in the general process of MPTNE genesis, there ultimately occurs (in a late phase after the binding of metabolites to the functional amino acid groups of proteins) a release, coupled with their tissue accumulation, of a heterogeneous, chemically diverse set of compounds grouped under the other scientific term "Post-Translational Modification Derived Products" (PTMDP). In short, all these products, thus released and accumulated, reflect the degree of modification and molecular aging of the proteins, and Therefore, as a consequence, cellular and tissue aging of the organism occurs. Among the main PTMDPs generated during the aforementioned MPTNEs, the most commonly described and discussed are methionine sulfoxide, dityrosine and 3-nitrotyrosine for the oxidation reaction, 4-hydroxy-2-nonenal-lysine, malondialdehyde-lysine, NE-carboxyethyl-lysine for the carbonylation reaction, homocitrulline for the carbamylation reaction (Jaisson S. et al., Médecine / Sciences, 2017, vol.33, pp.176-182 and references cited; Gillery P. et al., Clin. Chem. Lab. Med., 2013, vol.92, pp.228-238 and references cited).For non-enzymatic glycosylation and glycoxidation reactions of proteins, these PTMDPs can be, after a series of chain reactions and complex molecular rearrangements (formation of an unstable Schiff base then so-called Amadori molecular rearrangement), pentosidine, α-ketoaldehydes such as glyoxal, methylglyoxal or 3-deoxyglucosone (Gillery P. et al., Clin. Chem. Lab. Med., 2013, vol.92, pp.228-238 and references cited; Tessier FJ, Pathologie Biologie, 2010, vol.58, pp.214-219; ). Some of these PTMDPs generated during the aforementioned MPTNEs certainly constitute biomarkers of interest used in medical biology and aging, by allowing the experimental monitoring of a physiological process or age-related metabolic diseases (Gillery P., J. Med. Biochem., 2011, vol.30, ppp.201-206).However, based on another accepted and significant piece of knowledge, other PTMDPs, particularly those resulting from the spontaneous binding of reducing sugars to proteins, are considered true endogenous toxins at the molecular and cellular levels (Gillery P. et al., Clin. Chem. Lab. Med., 2014, vol. 52, pp. 33-38), to the point that the term "glycotoxins" also appears in the literature to designate, more broadly, all the harmful products and byproducts resulting from this process of binding reducing sugars to proteins (Monteiro-Alfredo T. et al., Diabetology, 2022, vol. 3, pp. 596-605). For informational purposes, this is indeed the case, for example, in an article with a concerning, albeit questioning, title: "Glycotoxins: a possible threat to health?" » (Odetti P. et al., Mediterr. J. Nutr. Metab., 2008, vol.l, pp.63-67), and in another more recent article that addresses the cytotoxicity exhibited by some of these glycotoxins once they are trapped within cells (Kuzan A., Biomed. Rep., 2021, vol. 14, pp. 1-8). The same lexical usage will be used throughout the following discussion. In any case, the accumulation of these "PTMDPs" entities during the aging process has been clearly demonstrated, particularly in the skin and blood vessels (Jaisson S. et al., Médecine / Sciences, 2017, vol. 33, pp. 176-182 and references cited). The present invention relates precisely to skin tissue through the search for means to counteract such glycotoxins and their resulting damaging effects, with the ultimate goal of counteracting them. The (molecular) aging process affects a specific type of skin protein: those with long half-lives, meaning proteins whose half-lives can reach several decades and which are therefore prime targets for cumulative and irreversible reactions such as MPTNEs (Jaisson S. et al., Médecine / Sciences, 2017, vol. 33, pp. 176-182). Three long-half-life proteins characteristic of the skin are particularly affected by this phenomenon: collagen, elastin, and fibronectin (Buszka A., Aesthetic Cosmetology and Medicine, 2023, vol. 12, pp. 23-278).Indeed, while the first two are essential for maintaining the structure and elasticity of the skin, and the third plays a key role in the organization of the dermis and its extracellular matrix, the aforementioned glycotoxins negatively exhibit the ability to produce and intensify the bridging process of intramolecular and intermolecular (transverse) cross-linking for these proteins. As a result, similar to collagen, a structural and supporting protein of the skin, the result is resistance to degradation by proteolytic enzymes commonly known as "MMPs" (matrix metalloproteinases), which hinder the replacement of aged protein fibers with newly synthesized fibers, ultimately leading to thickening protein fibrils.Beyond these aspects, a slowing of the skin wound healing process, stiffening and reduced elasticity of the skin tissue, and increased visibility of wrinkles are also reported in the aforementioned article "Buszka A." (Gkogkolou P. et al., Dermato-Endocrinology, 2012, vol. 4, pp. 259-270). Regarding strategies to combat the presence and harmful effects of such endogenous glycotoxins and / or those introduced through our modern Western diet, four concepts of so-called "general" action have recently been identified (Wang L. et al., Exp. Derm., 2024, vol. 33, el5065). Firstly, logically, coupled or not with that of strict blood glucose control, there is the option of a diet low in sugary foods and overly browned (grilled) cooked products since these are one of the determining factors in the production of glycotoxins (J. Uribarri et al., J. Am. Diet. Asso., 2010, vol.110, pp. 911-916). Then there is the option of a preventive, antioxidant action aimed at reducing oxidative processes. Indeed, knowledge of the biochemical reactions affecting the nature of proteins through the attachment of one or more sugars demonstrates that they are generally accompanied by oxidation reactions and that, as the aforementioned MPTNEs, the structural alterations that both cause in proteins are potentiated (Gillery P., J. Soc. Biol., 2001, vol. 195, pp. 387-390). Reference substances for this type of antioxidant agent include N-acetylcysteine, vitamins C and E, and quercetin (Wang L. et al., Exp. Derm., 2024, vol. 33, el5065). Finally, and most importantly, there is the action of multiple agents, purely synthetic or of natural origin, combined and sometimes reduced to their capacity as inhibitory agents, capable in any case of interacting on this unregulated condensation of sugars to proteins, and this at different stages (early or late) of said glycosylation and according to various modes of chemical action which some authors (Zheng W. et al., Nutrients, 2022, vol. 14, pp.1-19) have compiled into subcategories: "pre-Amadori inhibitors", "post-Amadori inhibitors", "crosslinking breakers", etc. (understanding for the latter entities capable of breaking the protein crosslinking already established). Some archetype molecules for these inhibitory agents are, in no particular order, pyridoxal-5'-phosphate, aspirin, aminoguanidine, pyridoxamine, benfotiamine, beta-alanyl-histidine, 4,5-dimethyl-3-phenacylthiazolium chloride (alagebrium) (Uceda AB et al., Biophys. Rev., 2024, vol.16, pp.189-218 and cited references) or rosmarinic acid, a natural phenolic compound found notably in rosemary (Velichkova S. et al., Planta Med., 2021, vol.87, pp.780-802). .

[0003] In any case, for the skin, and despite the availability of multiple and varied solutions designed to prevent / combat the presence / action of such PTMDPs and other glycotoxins, a limiting factor is identified within this body of general knowledge, and potentially, in fact, a cosmetic "challenge" of interest to manufacturers. Indeed, as illustrated by the very recent article "Wang L. et al." mentioned above and its conclusion, it is reported that studies conducted to date to evaluate the effect of these existing substances on the skin ultimately only show indications and a moderate action—described in English as "usually modest"—in reducing the damage caused by the cutaneous presence of these PTMDPs and other glycotoxins, and that this now results in a genuine need—even labeled in English as an "urgent need" in the aforementioned article "Wang L. et al."" - to develop increasingly effective / efficient agents for such a skin problem. This observation is also shared in the other very recent article mentioned above, "Uceda AB et al.", through the perspectives presented at the end of the article, where it is emphasized, more generally, that the clinical efficacy as well as the safety profile of these existing substances are not always fully established. The behavior on the skin of some of these existing substances, aminoguanidine for example, a reference inhibitor against the "RCCs" mentioned above, of interest for the scavenging of carbonyl intermediates, exhibits unfavorable side effects, notably, in the case of the aforementioned aminoguanidine, an increase in oxidative phenomena and a lupus-like skin rash (Song Q. et al., Biomed. Pharmacotherap., 2021, vol. 140, 111750).Thus, the present invention fits fully into the same challenge and need to make available [on the market] cosmetic and / or dermocosmetic active ingredients of interest for prevention. and the fight against molecular aging affecting skin proteins and its physiological consequences: modification of protein structure, function and antigenicity, modification of interactions between proteins and cells, etc. ] an agent that can constitute an alternative solution to current state-of-the-art ingredients, with however improved / increased / enhanced biological performance compared to the latter and the combined guarantee of safety for the user.More specifically, the applicant's objectives were to design and develop a new, original chemical entity with a number of advantageous technical effects, selected from, first and foremost, a proven and powerful efficacy on one or more given problems related to the molecular aging of slow-renewing proteins in the skin's extracellular matrix, high cutaneous bioavailability, stability both over time and in the formulation of the finished product, as well as established toxicology and safety of use. Description of the invention

[0004] The present invention was therefore developed in the context of the research and specifications as indicated above. The applicant, however, very quickly and deliberately opted for a molecular chemistry strategy that departs from a primary approach aimed at improving - by introducing a structural modification (grafting) such as with the prior assistance of in silico chemistry or artificial intelligence (both prevalent today for carrying out molecular design and / or predicting in vivo properties) - the biological behavior of any known prior art compounds of interest with respect to the non-enzymatic glycosylation process of proteins.And so it was that, within the framework of this option considered rather contrary to current trends, the applicant managed, surprisingly, to develop a new molecular complex combining in interaction (supramolecular chemistry) two substances - unmodified -.Specifically, and in particular in compliance with controlled ratios and conditions for obtaining such a molecular complex, the applicant has succeeded in associating, in the state of a complex stabilized by weak intermolecular bonds, two families of compounds each separately showing a history of interest in the formulation of cosmetic products, exemplified by their presence in the latest glossary of common names of cosmetic ingredients established by the European Commission through "Implementing Decision (EU) 2022 / 677 of 31 March 2022 laying down detailed rules for the application of Regulation (EC) No 1223 / 2009 of the European Parliament and of the Council", the latter having as a reminder and purpose of making cosmetic products sold in the European Union more. safe by establishing strict safety requirements to protect human health. In this case, the first of these families involved in the formation of the aforementioned molecular complex is a limited and specific selection of organosilanol derivatives developed by the applicant, with the following general formula (I):

[0005] (R)x-Si(OH)4 x (I)

[0006] in which:

[0007] - the radical R is a linear or branched Ci-C4> alkyl group, preferably in Ci-C2, possibly substituted by at least one hydroxyl group, preferably R is a methyl group, and

[0008] - x is equal to 1 or 2.

[0009] As for the second of these families involved in this new molecular complex, it is a limited and specific selection of organic compounds with an imidazole motif of the following general formula (II): (ID

[0010] in which:

[0011] - R! is -H, -CO2H or -CH2OH,

[0012] - R2 is:

[0013] i) let an alkyl chain of the following formula (III): (III)

[0014] in which: - R3 is -H or -NH2; - R4 is -CO2R5 or -NHR5, with R5 being -H or -COCH3; - n is equal to 1 or 2;

[0015] ii) let a heterocycle be chosen from:

[0016]

[0017]

[0018]

[0019]

[0020]

[0021]

[0022] The invention therefore has as its primary object an organic silicon complex formed between: a) an organosilanol of the following general formula (I): (R)x-Si(OH)4 x (I) in which: - the radical R is a linear or branched C1-C4 alkyl group, preferably C1-C2, possibly substituted by at least one hydroxyl group, preferably R is a methyl group, and - x is equal to 1 or 2; and b) at least one imidazole-motif organic compound of the following general formula (II), or one of its cosmetically or dermocosmetically acceptable salts:

[0023]

[0024]

[0025]

[0026] in which: - R! is -H, -CO2H or -CH2OH. - R2 is: i) consider an alkyl chain of the following formula (III): (in)

[0027] in which: - R3 is -H or -NH2; - Ri is -CO2R5 or -NHR5, with R5 being -H or -COCH3; - n is equal to 1 or 2;

[0028] ii) let a heterocycle be chosen from:

[0029] said complex being formed via the establishment of at least one (for example two or three) weak bond, preferably at least one (for example two or three) hydrogen bond, between at least one (for example two or three) hydroxyl group of said organosilanol of general formula (I) and said at least one imidazole motif organic compound of general formula (II), preferably at the level of at least one (for example two or three) of the nitrogen and oxygen atoms of said at least one imidazole motif organic compound of general formula (II);

[0030] the molar ratio between said organosilanol of general formula (I) and said at least one imidazole motif organic compound of general formula (II) being between about 0.1 and about 1 (for example between 0.1 and 1).

[0031] According to one embodiment, the complex according to the invention is formed via the establishment of weak bonds, preferably hydrogen bonds, between the hydroxyl groups of said organosilanol of general formula (I) and the nitrogen and oxygen atoms of said at least one imidazole motif organic compound of general formula (II).

[0032] Without being bound by theory, imidazole-motif organic compounds of general formula (II) act as organosilanol stabilizing agents by forming at least one weak bond, preferably at least one hydrogen bond, with at least one hydroxyl group of said organosilanol of general formula (I), as explained above. As such, they may also be called "organosilanol stabilizing agents" (or, more simply, "stabilizing agents").

[0033] After extensive research, the applicant's choice ultimately fell on such a new chemical entity and intermolecular association, in the form of a "complex" as defined by the nomenclature rules of the International Union of Pure and Applied Chemistry ("IUPAC" in French, or "IUPAC" in English for "International Union of Pure and Applied Chemistry"), due to the generally advantageous and promising behavior that said complex according to the invention has displayed through a range of beneficial technical effects, particularly the experimental superiority that said complex according to the invention has shown compared to each of its constituent elements taken in isolation (to be understood as "not engaged in the same complex state"), illustrated by: - its ability to very significantly limit the formation of a glycosylated protein produced by the contact of a highly reactive dicarbonyl compound (generated from a glucose derivative after an Amadori molecular rearrangement as mentioned on the previous page), namely glucosone, with an analytical reference protein (stable and devoid of enzymatic activity), namely bovine serum albumin better known by the usual English acronym "BSA" [see test 1 below]; - its ability to significantly reduce the secretion of a matrix metalloproteinase (MMP) type proteolytic enzyme that is unfavorable to the renewal of fibrillar collagen in the skin's extracellular matrix, in this case "MMP-1" as mentioned on the previous page, the latter being secreted following the deleterious induction (stress) of the aforementioned glucosone on cultured fibroblastic cells (acronym "NHDF" in English for "Normal Human Dermal Fibroblasts") [see test 2 below]; - finally, its ability to significantly stimulate the expression of another long half-life protein as mentioned on the previous page, fibronectin, a structural protein with a key role in the adhesion / fixation of dermal cells to this same extracellular matrix of the skin (Jacob MP, Médecine / Sciences, 2006, vol.22, pp.273-278) [cf. test 3 below].

[0034] Moreover, and this is one of the foundations of the present invention, a particularly unexpected synergistic effect has been observed for such a complex, which combines, by weak bonds, the aforementioned organosilanol of general formula (I) and the aforementioned at least one imidazole-motif organic compound of general formula (II). Indeed, the said molecular complex state, coupled with its compositional characteristics, has made it possible, on the one hand, to significantly oppose the formation of "BSA-glucosone" (glycotoxin), and on the other hand, to stimulate the skin-beneficial protein expression of fibronectin, and this in a much more effective manner—a far superior effect—than the organosilanol of general formula (I) alone, or the same imidazole-motif organic compound of general formula (II) alone.

[0035] Such a synergy of action is thus legitimately formulated: - in view of the theoretical teaching provided for the use of such a phrase in the field of chemical products and substances, in particular the fact that (sic) "there is a synergistic effect when the combined effect of two chemical products is much greater than the sum of the effects of each product taken individually. For example: 2 + 2" 4" \ https: / / www.cchst.ca / oshanswers / chemicals / synergism.html ] ; - in light of the experimentation and results obtained in each of the studies, since the association of the two components, in the form of a complex molecular, allows to obtain a much better effect than that obtained, at equivalent use concentrations, for each of them taken individually.

[0036] It is further legitimately stated that this specific mode of action, with this objective phenomenon of synergistic action, allows the biological behavior of the aforementioned complex illustrated to be described as "optimal" or "endowed with optimal properties" for the protection of long-lived skin proteins (collagen, elastin, and fibronectin) against their molecular aging, that is to say, all the non-enzymatic modifications that these proteins naturally undergo and that lead to alterations in their structural and functional properties. Finally, it is legitimately stated that a "complex" (molecular) state is formed and exists, given, on the one hand, the definitions of "complex" and "hydrogen bond" established by the International Union of Pure and Applied Chemistry ("IUPAC" in French), and on the other hand, for the selected imidazole-motif organic compounds, their electron-rich regions,characterized by the presence of non-bonding electron pairs on certain nitrogen and oxygen atoms, which are conducive to the establishment of such "hydrogen bond" type interactions. However, although the applicant has already claimed the same "complex" state and weak bonds for the methylsilanetriol derivative associated with a deoxy-aldohexose monomeric sugar (patent FR3038898), alternatively for the methylsilanetriol derivative associated with calibrated fragments of hyaluronic acid with molecular weights between 150 and 750 kDa (patent EP2172186), or even for the methylsilanetriol derivative coexisting with a second organosilanol, both associated via a mixture of weak and covalent bonds,to a panel of stabilizing agents (patent EP4153603) – the latter clearly distinct, however, from the present selection of imidazole-motif organic compounds of general formula (II) – the aforementioned organosilanol derivatives of general formula (I) and imidazole-motif organic compounds of general formula (II) have never been combined to create such a "complex" state, nor for its use for cosmetic and / or dermocosmetic purposes with respect to long-lived proteins, in particular fibronectin. Furthermore, any synergistic effect between the aforementioned organosilanols of general formula (I) and imidazole-motif organic compounds of general formula (II), whether in a "complex" state or not (simple association), has never been described or even anticipated in the prior art. Furthermore, in accordance with the objectives attached to the technical problem posed by the present invention,the aforementioned complex according to the present invention de facto, by virtue of the fact that its constituent elements taken separately (for many of them) belong to the aforementioned Implementing Decision (EU), 2022 / 677 highlights the importance of complying with European cosmetic and chemical regulations (respectively Regulations (EC) No 1223 / 2009 and No 1907 / 2006 of the European Parliament and of the Council) aimed at ensuring consumer safety. Furthermore, a wide range of toxicological assessment data is available – some dating back quite some time and therefore "reassuring" for formulators of finished products – concerning some of the aforementioned organosilanol derivatives with general formula (I) and imidazole-motif organic compounds with general formula (II).

[0037] According to one embodiment of the invention, said organosilanol of general formula (I) is monomethylsilanetriol or dimethylsilanediol, preferably monomethylsilanetriol.

[0038] According to a preferred embodiment of the invention, said at least one imidazole-motif organic compound of general formula (II) is such that: - Ri is -H or -CO2H; and - R2 is an alkyl chain of formula (III) in which: • R3 is -H, • R4 is -NHR5 with R5 being -H or -COCH3 • n is equal to 1.

[0039] According to a preferred embodiment of the invention, said at least one imidazole-motif organic compound of general formula (II) is such that: - Ri is -H or -CO2H; and - R2 is an alkyl chain of formula (III) in which: • R3 is -H, • R4 is -NHR5 with R5 being -H, • n is equal to 1.

[0040] According to a preferred embodiment of the invention, said at least one imidazole-membered organic compound of general formula (II) is the compound 3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide, the compound 3-acetamido-N-[2-(1H-imidazol-5-yl)ethyl]propanamide, the compound (2S)-2-(3-aminopropanoylamino)-3-(1H-imidazol-5-yl)propanoic acid, and / or the compound (4S)-4-amino-5-[2-(1H-imidazol-5-yl)ethylamino]-5-oxopentanoic acid. Advantageously, it is the compound 3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide.

[0041] The salts of said at least one imidazole motif organic compound of general formula (II), in particular of the aforementioned preferred compounds, can be obtained by reaction of said derivatives and compounds with an inorganic acid, preferably hydrochloric acid, or an organic acid, in particular said cosmetically or dermocosmetically acceptable salt according to the invention is a hydrochloride.

[0042] In a preferred embodiment of the invention, said organosilanol of general formula (I) and said at least one imidazole motif organic compound of general formula (II) are respectively monomethylsilanetriol and 3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide.

[0043] In a preferred embodiment of the invention, the claimed complex is such that the molar ratio between the aforementioned organosilanol of general formula (I) and the aforementioned at least one imidazole-motif organic compound of general formula (II) is between about 0.15 and about 0.8 (for example between 0.15 and 0.8), advantageously between about 0.2 and about 0.6 (for example between 0.2 and 0.6), even more advantageously between about 0.3 and about 0.5 (for example between 0.3 and 0.5).

[0044] In a preferred embodiment of the invention, the complex according to the invention is in liquid form, advantageously in the form of a solution.

[0045] Advantageously, the complex according to the invention is such that:

[0046] i) the molar ratio between the aforementioned organosilanol of general formula (I) (for example, monomethylsilanetriol) and the aforementioned at least one imidazole-membered organic compound of general formula (II) (for example, the compound 3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide) is between approximately 0.15 and approximately 0.8 (for example, between 0.15 and 0.8), more advantageously between approximately 0.2 and approximately 0.6 (for example, between 0.2 and 0.6); particularly preferably, said molar ratio being approximately 0.4 (for example, 0.4), and / or

[0047] ii) the pH of the composition (in liquid form, advantageously in solution form) comprising said complex is between about 3 and about 8 (for example between 3 and 8), preferably between about 4 and about 6 (for example between 4 and 6);

[0048] preferably, said complex and the liquid composition comprising it (advantageously in solution form) having the characteristics i) and ii) as illustrated by its preparation process [see test 4 below].

[0049] The invention also relates to a composition, preferably in liquid form, advantageously in solution form, comprising, or consisting essentially of, at least one complex according to the invention.

[0050] The invention also relates to a cosmetic or dermocosmetic composition, characterized in that said composition comprises (or essentially consists of), in association with at least one cosmetically or dermocosmetically acceptable excipient, at least one complex according to the invention, preferably said composition being in a form suitable for topical cutaneous administration and said at least one excipient being further physiologically acceptable to the skin. Advantageously, the quantity of said complex according to the invention in the aforementioned compositions is between 1% and 10% by weight relative to to the total weight of said composition, preferably between 3% and 7% by weight relative to the total weight of said composition. For guidance purposes only and not as a limitation, when the aforementioned cosmetic or dermocosmetic compositions are suitable for topical cutaneous administration, they may be presented in all forms normally used for such a route of administration.Thus, and advantageously, they can be presented in liquid form, advantageously as a solution (for example, as an aqueous or hydroalcoholic solution), possibly gelled, as a lotion-type dispersion possibly biphasic, as an oil-in-water or water-in-oil emulsion, as a suspension, as a lotion, as a cream, as an aqueous or hydroalcoholic gel, or even as a powder (micronized), as a foam, as a serum, as a paste, as a suspension, as a dispersion or as multiple emulsions which may possibly be microemulsions or nanoemulsions.In terms of adjuvants present in the above-mentioned compositions and physiologically compatible with the skin, we can mention a compound chosen from among oils, waxes, silicone elastomers, surfactants, co-surfactants, solubilizers, co-solubilizers, thickeners and / or gelling agents, humectants, emollients, organic or inorganic sunscreens, photostabilizers, preservatives with the exception of aldehyde-donating preservatives, colorants, abrasive fillers, pearlescent agents, mattifying agents, tightening agents, sequestering agents, perfumes, etc., and their mixtures.By way of example and not limitation, such an acceptable adjuvant in the fields of application covered by the present invention, present in the formula at a concentration of approximately 0.01 to 20% by weight relative to the total weight of the aforementioned composition, preparation, and other supplement, is notably cited in the "International Cosmetic Ingredient Dictionary and Handbook" published by the Personal Care Product Council (PCPC) of the American Cosmetic Association. Finally, these same compositions mentioned above may include at least one additional active ingredient, provided that those skilled in the art ensure that any additional active ingredients, as well as their proportions, are chosen in such a way that the beneficial properties attributed to these compositions are not, or not substantially, altered by the intended addition.Such additional active ingredients may be chosen, without this list being exhaustive, from among depigmenting agents, photoprotective agents, barrier function stimulating agents, moisturizing or humectant agents, desquamating agents, soothing agents, exfoliating agents, agents stimulating cell proliferation such as fibroblasts and keratinocytes, deglycosylating agents, agents stimulating the synthesis of collagen or elastin or preventing their degradation, agents stimulating the synthesis of glycosaminoglycans or proteoglycans or preventing. their degradation, antioxidant or free radical scavenging or anti-pollution agents, lipolysis-stimulating agents, draining or detoxifying agents, anti-inflammatory agents, penetration accelerators, desquamating agents, soothing and / or anti-irritant agents, astringent agents, exfoliating agents, agents acting on microcirculation, etc., and mixtures thereof, such additional active ingredient being present in the formula in a content of approximately 0.0001 to 20% by weight, preferably 0.01 to 5% by weight, relative to the total weight of the aforementioned composition.

[0051] The invention also relates to the non-therapeutic cosmetic or dermocosmetic use of a complex according to the invention as defined above, or of a cosmetic or dermocosmetic composition as defined previously, to maintain and / or increase the expression of proteins in the extracellular matrix of healthy skin, preferably said use being topical cutaneous application. Advantageously, said protein in the extracellular matrix of healthy skin is fibronectin.

[0052] According to a preferred embodiment, the non-therapeutic cosmetic or dermocosmetic use of a complex according to the invention as defined above, or of a cosmetic or dermocosmetic composition according to the invention as defined above, is:

[0053] a) to maintain and / or increase the biomechanical properties of healthy skin, preferably the firmness and / or elasticity of healthy skin;

[0054] b) to prevent and / or correct signs of aging of healthy skin (in particular induced by non-enzymatic glycosylation of long half-life proteins, preferably that affecting fibronectin);

[0055] c) to prevent and / or correct tissue fibrosis associated with skin aging;

[0056] d) as an agent to combat the stiffening of the walls of dermal capillaries;

[0057] e) to restore the cutaneous vascular network altered with age; and / or

[0058] f) as an inhibitory agent on the overproduction of matrix metalloproteinase MMP-1 (induced by non-enzymatic glycosylation of long half-life proteins, preferably those affecting collagen).

[0059] As indicated previously, the aforementioned non-therapeutic cosmetic or dermocosmetic use is intended for "healthy" skin - or area(s) of healthy skin - as opposed to "disease" skin - or area(s) of diseased skin - exhibiting a skin pathology.

[0060] In the case of topical cutaneous administration, this use is carried out on one or more area(s) of "healthy" skin, that is to say one or more area(s) of skin not affected by a skin pathology.

[0061] According to a particular embodiment, the aforementioned non-therapeutic cosmetic or dermocosmetic use is carried out on an individual without any skin pathology. This individual is referred to, in the context of the present invention, as a "healthy subject," as opposed to a "sick subject" with a skin pathology.

[0062] Another object of the invention relates to the use of at least one imidazole-motif organic compound of the following general formula (II), or one of its cosmetically or dermocosmetically acceptable salts:

[0063] in which:

[0064] - R! is -H, -CO2H or -CH2OH,

[0065] - R2 is:

[0066] i) let an alkyl chain of the following formula (III): (neither)

[0067] in which: - R3 is -H or -NH2; - R4 is -CO2R5 or -NHR5, with R5 being -H or -COCH3; - n is equal to 1 or 2;

[0068] ii) let a heterocycle be chosen from:

[0069] to stabilize an organosilanol of the following general formula (I):

[0070] (R)x-Si(OH)4 x (I)

[0071] in which:

[0072] - the radical R is a linear or branched Ci-C4> alkyl group, preferably in Ci-C2, possibly substituted by at least one hydroxyl group, preferably R is a methyl group, and

[0073] - x is equal to 1 or 2.

[0074] Definitions

[0075] General definitions

[0076] By "organic silicon", one should understand one or more organosilanol compound(s).

[0077] By "glycotoxin", one must understand all the deleterious products and by-products resulting from the process of the attachment of reducing sugars to proteins.

[0078] By "complex" or "molecular complex" is to be understood a molecular entity formed by a free association between two or more component molecular entities (ionic or uncharged), or the corresponding chemical species, the bond between the components being normally weaker than in the case of a covalent bond (Source: IUP AC, 1994, 66, 1077 -Glossary of terms used in physical organic chemistry - IUP AC - Recommendations 1994 - on page 1098).

[0079] By “hydrogen bonding,” we mean an attractive interaction between a hydrogen atom of a molecule or molecular fragment XH in which X is more electronegative than H, and an atom or group of atoms of another molecule. A typical hydrogen bond can be represented by XH”“YZ, where the three dots denote the bond and XH represents the hydrogen bond donor, the acceptor being an electron-rich region such as a lone pair on Y. Evidence for hydrogen bond formation can be experimental or theoretical, or a combination of both (Henry M., Interference International Review of Science, 2015, and references cited).

[0080] By "in systematic nomenclature IUPAC", it is meant a designation according to a standardized system of chemical compounds based on the application of the strictest recommendations established by the International Union of Pure and Applied Chemistry (IUPAC). of Pure and Applied Chemistry"), recommendations which aim to ensure that a name corresponds to one and only one molecular structure.

[0081] By "synergy of action," it is meant that there is a synergistic effect when the combined effect of two chemicals is greater than the sum of the effects of each chemical taken individually. For example: 2 + 2 ≈ 4.

[0082] [https: / / www.cchst.ca / oshanswers / chemicals / synergism.html].

[0083] By "in compliance with controlled ratios and conditions for obtaining such a molecular complex", it is necessary to understand a molar ratio of organosilanol derivative of formula (I) to imidazole-motif organic compound of general formula (II), established after a comparative screening of multiple tests aimed at defining a ratio between these two entities, capable of giving the complex according to the invention a biological behavior on the skin that can be as favorable as possible, as well as the identification of operating conditions which allow to maintain simultaneously a solubilization of the organosilanol entities of formula (I) and imidazole-motif organic compound of general formula (II) as well as a stabilization of the former (and its free hydroxyl groups) by the latter.

[0084] By "hydrochloride," we mean the product of addition (salt) of hydrochloric acid with a nitrogenous organic base. This may be, for example, a chloride, a dichloride, etc.

[0085] Definitions inherent to the cosmetic and dermocosmetic (non-therapeutic) field

[0086] By "long half-life skin protein", we mean extracellular matrix proteins whose half-lives reach several decades, and which are preferred targets of molecular aging (Jaisson S. et al., Médecine / Sciences, 2017, vol.33, pp. 176-182).

[0087] By "age-associated tissue fibrosis", we must understand the predisposition of the proteins of the skin's extracellular matrix to develop, with aging, a tissue fibrotic process caused by the numerous modifications (MPTNEs) or "Non-Enzymatic Post-Translational Modifications" (glycosylation, cross-linking, matrix rigidity, etc.) to which these same proteins are subject (Selman M. et al., Ageing Res. Rev., 2021, vol.70, 101393). Detailed description

[0088] The detailed description below is intended to set out the invention in a sufficiently clear and complete manner, in particular by means of examples, but shall in no case be regarded as limiting the scope of protection to the particular embodiments and examples presented below. Examples

[0089] Example 1: Two illustrations of a composition formulation according to the invention, for cosmetic or dermocosmetic purposes, are mentioned below, both containing a complex according to the aforementioned invention:

[0090] Formula A (cream)

[0091] Complex according to the invention [monomethylsilanetriol / 3-amino-N-[2-(lH-imidazol-5- yl)ethyl]propanamide (IUPAC)]: 5%

[0092] Hydrogenated polyisobutene: 7%

[0093] Isobutyl myristate: 3%

[0094] Cetyl palmitate: 7%

[0095] Sorbitan laurate: 2%

[0096] Polysorbate 20: 2%

[0097] Carbomer (acrylate / acrylamide copolymer & mineral oil): 0.3%

[0098] Phenoxyethanol: 0.5%

[0099] Water: q.s. 100%

[0100] Formula B (gel)

[0101] Complex according to the invention [dimethylsilanediol / acid(2S)-2-(3- aminopropanoylamino)-3-(lH-imidazol-5-yl)propanoic acid (IUPAC)]: 5%

[0102] Carbomer (acrylate / acrylamide copolymer & mineral oil): 1.5%

[0103] Sodium benzoate: 0.2%

[0104] Sorbic acid: 1%

[0105] 1,3-butanediol: 10%

[0106] Glycerin: 5%

[0107] Sodium hydroxide: 0.13%

[0108] Phenoxyethanol: 0.9%

[0109] Water: q.s. 100%

[0110] Example 2: The invention is illustrated below, for illustrative purposes only, by the following tests mentioned above in the description of the invention (tests 1 to 4)

[0111] Test 1: Demonstration of the ability of the complex according to the invention to limit the formation of "BSA-glucosone"

[0112] The evaluation of the formation of "BSA-glucosone" by a complex according to the invention is carried out in tubo under the conditions defined below, based in particular on data from the literature (Grzecgorczyk-Karolak I. et al., Molécules, 2016, vol. 21, 739). Specifically, bovine albumin protein (BSA) (ref. Sigma A3912 - lot no. SLBJ0078V), at a concentration of 1 mg / ml, is incubated with D-glucosone (or 2-keto-D-glucose), namely a reactive carbonyl compound ("RCC" above) produced by an Amadori rearrangement from a glucose derivative. Thus, 0.5 mM of D- Glucosone (ref. Sigma 61793 - lot no. BCCK7499) is dissolved in ultrapure water and then placed under the following conditions: pH 7.4, in the dark, at a temperature of 50°C, for 2 days. Before incubation, a solution of the compounds to be tested in ultrapure water is added to the above mixture. The formation of "BSA-glucosone" is measured by fluorimetry (excitation X-ray: 340 nm; emission X-ray: 470 nm) by calculating the percentage of "BSA-glucosone" formation using the following equation:

[0113] [Math.l] % BSA—glucosone =----------■------------- x 1Û0

[0114] in which: - "Ftreatment" expresses the fluorescence intensity of the compound to be tested incubated with D-glucosone in the presence of BSA; - "Ftraitementbianc" expresses the fluorescence intensity of the compound to be tested incubated with D-glucosone in the absence of BSA; - "Fcontrôie" expresses the fluorescence intensity of D-glucosone in the presence of BSA; - "Fcontrôie bianc" expresses the fluorescence intensity of D-glucosone in the absence from the BSA.

[0115] The results, repeated four times, are summarized in Table 1 below, referred to as [Table 1]. They are expressed, in particular, as a percentage reduction in the quantity of "BSA-glucosone" produced. They were obtained for the following different configurations:

[0116] - case 1, namely:

[0117] . the "control", i.e. the "BSA-glucosone" generated by contacting the glucosone on the BSA and in the absence of treatment;

[0118] - case 2, namely:

[0119] . the compound monomethylsilanetriol [batches no. E17796 and 18521] which is the subject of formula (I) above in which R = CH3 (methyl) and x = 1, tested alone;

[0120] - case 3, namely:

[0121] . the compound 3-amino-N-[2-(lH-imidazol-5-yl)ethyl]propanamide [lot no. E17797] object of formula (II) above in which Ri = H, R2 is an alkyl chain of formula (III) in which R3 is -H, R4 is -NHR5 with R5 being -H, n is equal to 1, tested alone;

[0122] - case 4, namely:

[0123] . the acidic compound (2S)-2-(3-aminopropanoylamino)-3-(1H-imidazol-5- yl)propanoic [ref. Sigma C9625- lot no. BCCB1338], subject of formula (II) above in which Ri = CO2H, R2 is an alkyl chain of formula (III) in which R3 is -H, R4 is -NHR5 with R5 being -H, n is equal to 1, tested alone;

[0124] - case 5, namely:

[0125] . the acidic compound (4S)-4-amino-5-[2-(1H-imidazol-5-yl)ethylamino]-5- oxopentanoic [lot no. 5116.24], subject of formula (II) above in which Ri = H, R2 is an alkyl chain of formula (III) in which R3 is NH2, R4 is -CO2R5 with R5 being -H, n is equal to 2, tested alone;

[0126] - case 6, namely:

[0127] . the complex according to the invention, in aqueous solution [batch no. E17767], combining (hydrogen bonds) the aforementioned "monomethylsilanetriol compound" (case 2) and "3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide compound" (case 3) in the molar ratio of 0.4;

[0128] - case 7, namely:

[0129] . the complex according to the invention, in aqueous solution [batch no. E18562], combining (hydrogen bonds) the aforementioned "monomethylsilanetriol compound" (case 2) and "(2S)-2-(3-aminopropanoylamino)-3-(1H-imidazol-5-yl)propanoic acid compound" (case 4) in the molar ratio of 0.36;

[0130] - case 8, namely:

[0131] . the complex according to the invention, in aqueous solution [batch no. E18564], combining (hydrogen bonds) the aforementioned "monomethylsilanetriol compound" (case 2) and "(4S)-4-amino-5-[2-(1H-imidazol-5-yl)ethylamino]-5-oxopentanoic acid compound" (case 5) in the molar ratio of 0.38.

[0132] [Tables 1] Compound (concentration) Quantity (%) of BSA-glucosone Decrease (%) on BSA-glucosone production Case 1 [control] 100 N / A Case 2 (0.0625%) 98 - 2 Case 3 (0.0625%) 99 - 1 Case 6 [according to the invention] (0.0625%) 87 - 13 Case 2 (0.625%) 100 0 Case 4 (0.625%) 104 + 4 Case 7 [according to the invention] (0.625%) 78 - 22 Case 2 (0.625%) 100 0 Case 5 (0.625%) 96 - 4 Case 8 [according to the invention] (0.625%) 71 - 29

[0133] The results highlight, for the complexes according to the invention, unlike their two constituent elements taken in isolation, an ability to limit the formation of "BSA-glucosone" by an objective phenomenon of synergistic action, moreover for case 6 from a very low concentration of active ingredient of 0.0625% (50 pM).

[0134] Test 2: Demonstration of the ability of the complex according to the invention to inhibit the secretion of the matrix metalloproteinase proteolytic enzyme "MMP-1" involved in collagen proteolysis

[0135] Experimentally, the test is performed on primary reticular and papillary fibroblast cells (abbreviated "NHDF" for "Normal Human Dermal Fibroblasts") obtained following isolation from a breast reconstruction (Alphenyx, lot 19-01-21001, 32-year-old patient). These NHDFs, originally maintained at 37°C in a humid atmosphere containing 5% CO2, are The cells were then cultured in a complete culture medium "DMEM" (with 4.5 g / L of glucose supplemented with 10% fetal bovine serum (FBS) and 1% glutamine). On day -3, the fibroblasts were seeded into 6-well plates at a density of 3 x 10⁴ cells / cm². On day 0, the cells were pretreated with the reference inhibitor, aminoguanidine (ref. Sigma: 396494 - lot no. MKCL5504), or with the compounds to be tested. Treatments were carried out in "DMEM advanced" medium (DMEM with 4.5 g / L of glucose and 2.5 mg / L of ascorbic acid) supplemented with 1% FBS for 7 days. On day +7, the stress agent "RCC" (D-glucosone), at a concentration of 300 µM, was then incubated for a new period of 7 days, in the presence of the reference inhibitory agent or in the presence of the compounds to be tested.At day 14 (i.e., 14 days of treatment in total, including 7 days in the presence of D-glucosone), the culture supernatants were collected to perform an ELIS A assay of the matrix metalloproteinase "MMP-1" ("Abcam kit, ref. ab215083"). The results obtained were then subjected to triplicate statistical analysis. The results, repeated three times, are summarized in Table 2 below. They are expressed, in particular, as a percentage of inhibition of "MMP-1" secretion. They were obtained for the following different configurations:

[0136] - case 1, namely:

[0137] . the "control" (without adding a complex according to the invention);

[0138] - case 2, namely:

[0139] . the reference inhibitory agent, with the molecule "aminoguanidine" [ref. Sigma: 396495];

[0140] - case 3, namely:

[0141] . the compound monomethylsilanetriol [batches no. E17855 and E18292] which is the subject of the formula (I) above in which R = CH3 (methyl) and x = 1, tested alone;

[0142] - case 4, namely:

[0143] . the compound 3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide [batch no. E17797 and 182291] object of formula (II) above in which Ri = H, R2 is an alkyl chain of formula (III) in which R3 is -H, R4 is -NHR5 with R5 being -H, n is equal to 1, tested alone;

[0144] - case 5, namely:

[0145] . the complex according to the invention, in aqueous solution [batch no. E17844 and E18290], combining (hydrogen bonds) the aforementioned "monomethylsilanetriol compound" (case 3) and "3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide compound" (case 4) in the molar ratio of 0.4.

[0146] [Tables2] Compound (concentration) MMP-1 secretion (%) Inhibition (%) MM secretion Pl Case 1 [control] 100 N / A Case 2 [reference] (600 pM) 63 -37 Case 3 (0.1%) 77 23 Case 4 (0.1%) 82 18 Case 5 [according to the invention] (0.1%) 70 30

[0147] The results highlight, for the complex according to the invention, a significantly greater capacity, compared to its two constituent elements taken in isolation, to inhibit the secretion of MMP-1.

[0148] Test 3: Demonstration of the ability of the complex according to the invention to stimulate fibronectin expression

[0149] Experimentally, the test is performed on the same primary reticular and papillary fibroblast cells as in Test 2 above, namely that said NHDF cells are cultured identically in a complete culture medium "DMEM" (with 4.5 g / L of glucose supplemented with 10% fetal bovine serum (FBS) and 1% glutamine). On day 1 after seeding, the cells are treated for 3 days in the presence of the compounds to be tested. The cells are then fixed for fluorescence immunostaining of fibronectin using a specific antibody "anti-fibronectin (Abcam, ref. ab2413)" and then detected with a secondary antibody "Alexa Fluor 488® (Invitrogen, ref. Al 1008)". The marking was then observed using an Olympus BX60 epifluorescence microscope at 20x magnification for each condition. Photographs were taken with an Olympus DP72 camera, with three photographs per condition.Finally, the average fluorescence intensity of the labeling was quantified using image analysis software ("ImageJ®"). The results for each condition were compared to the control condition. The results, presented as average percentages (in triplicate, n=3), are summarized in Table 3 below [Table 3]. They are expressed, in particular, as a percentage of stimulation on fibronectin expression. They were obtained for the following different configurations:

[0150] - case 1, namely:

[0151] . the "control" (without the addition of an active ingredient);

[0152] - case 2, namely:

[0153] . the compound monomethylsilanetriol [lot no. E18443], subject of formula (I) above in which R = CH3 (methyl) and x = 1, tested alone;

[0154] - case 3, namely:

[0155] . the compound 3-amino-N-[2-(lH-imidazol-5-yl)ethyl]propanamide [lot no. E18398] object of formula (II) above in which Ri = H, R2 is an alkyl chain of formula (III) in which R3 is -H, R4 is -NHR5 with R5 being -H, n is equal to 1, tested alone;

[0156] - case 4, namely:

[0157] . the complex according to the invention, in aqueous solution [batch no. E18442], combining (hydrogen bonds) the aforementioned "monomethylsilanetriol compound" (case 2) and "3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide compound" (case 3) in the molar ratio of 0.4.

[0158] [Tables3] Compound (concentration) Fibronectin expression (%) Increase (%) Fibronectin expression Case 1 [control] 100 N / A Case 2 (0.1%) 104 + 4 Case 3 (0.1%) 121 + 21 Case 4 [according to the invention] (0.1%) 138 + 38

[0159] The results highlight, for the complex according to the invention, compared to its two constituent elements taken in isolation, a much greater capacity, moreover even by an objectified phenomenon of synergy of action, to stimulate the expression of fibronectin.

[0160] Test 4: process for preparing an organic silicon complex according to the invention (namely the above-mentioned complex such as said organosilanol of general formula (I) and said imidazole motif organic compound of general formula (II) being respectively monomethylsilanetriol and the compound 3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide)

[0161] 20 g (78 mmol) of compound 3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide), in its hydrochloride form, are dissolved in 720 g of demineralized water. Under pH control (between 3 and 8) and adjustment with an HCl solution, a commercial solution (7.25 g) of sodium methylsiliconate (32 mmol), previously Diluted in approximately 96 ml of water, the solution is gradually added to the previous solution while stirring, at room temperature. The mass of the solution is then adjusted to 1 kg by adding demineralized water. The resulting complex solution (molar ratio of 0.4 between monomethylsilanetriol and the compound 3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide) is then adjusted to a pH of 4.9 using a few drops of HCl. A clear, colorless, and odorless solution is obtained.

Claims

1. Demands Organic silicon complex formed between: a) an organosilanol of the following general formula (I): (R)x-Si(OH)4 x (I) in which: - the radical R is a linear or branched CrC4 alkyl group, preferably Ci-C2, possibly substituted by at least one hydroxyl group, preferably R is a methyl group, and - x is equal to 1 or 2; and b) at least one imidazole-motif organic compound of the following general formula (II), or one of its cosmetically or dermocosmetically acceptable salts: hn""V y* y R, G (H) in which: - R! is -H, -CO2H or -CH2OH. - R2 is: i) consider an alkyl chain of the following formula (III): (IH) in which: - R3 is -H or -NH2; - R4 is -CO2R5 or -NHR5, with R5 being -H or -COCH3; - n is equal to 1 or 2; ii) let a heterocycle be chosen from: said complex being formed via the establishment of at least one weak bond, preferably at least one hydrogen bond, between at least one hydroxyl group of said organosilanol of general formula (I) and said at least one imidazole-modified organic compound of general formula (II), preferably at the level of at least one of the nitrogen and oxygen atoms of said at least one imidazole-modified organic compound of general formula (II); the molar ratio between said organosilanol of general formula (I) and said at least one imidazole-modified organic compound of general formula (II) being between about 0.1 and about 1.

2. Complex according to claim 1, wherein said organosilanol of general formula (I) is monomethylsilanetriol or dimethylsilanediol, preferably monomethylsilanetriol.

3. Complex according to any one of the preceding claims, wherein said at least one imidazole motif organic compound of general formula (II) is such that: - Ri is -H or -CO2H; and - R2 is an alkyl chain of formula (III) in which: • R3 is -H, • R4 is -NHR5 with R5 being -H or -COCH3, • n is equal to 1.

4. Complex according to any one of the preceding claims, wherein said at least one imidazole-motif organic compound of general formula (II) is the compound 3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide, the compound 3-acetamido-N-[2-(1H-imidazol-5-yl)ethyl]propanamide, the compound (2S)-2-(3-aminopropanoylamino)-3-(1H-imidazol-5-yl)propanoic acid, and / or the compound (4S)-4-amino-5-[2-(1H-imidazol-5-yl)ethylarnino]-5-oxopentanoic acid; preferably said at least one imidazole-motif organic compound of general formula (II) being the compound 3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide.

5. Complex according to any one of the preceding claims, wherein said cosmetically or dermocosmetically acceptable salt of said at least one imidazole motif organic compound of general formula (II) is a hydrochloride.

6. Complex according to any one of the preceding claims, wherein said organosilanol of general formula (I) and said at least one imidazole motif organic compound of general formula (II) are respectively monomethylsilanetriol and 3-amino-N-[2-(1H-imidazol-5-y1)ethy1]propanamide.

7. Complex according to any one of the preceding claims, wherein the molar ratio between said organosilanol of general formula (I) and said at least one imidazole motif organic compound of general formula (II) is between 0.15 and 0.8, advantageously between 0.2 and 0.

6.

8. Cosmetic or dermocosmetic composition, characterized in that said composition comprises, in association with at least one cosmetically or dermocosmetically acceptable excipient, at least one complex according to one of the preceding claims, preferably said composition being in a form suitable for topical cutaneous administration and said at least one excipient being further physiologically acceptable with the skin.

9. A cosmetic or dermocosmetic composition according to the preceding claim, characterized in that said composition further comprises at least one additional active ingredient selected from among depigmenting agents, photoprotective agents, barrier function stimulating agents, moisturizing or humectant agents, desquamating agents, soothing agents, exfoliating agents, agents stimulating cell proliferation such as fibroblasts and keratinocytes, deglycosylating agents, agents stimulating collagen or elastin synthesis or preventing their degradation, agents stimulating glycosaminoglycan or proteoglycan synthesis or preventing their degradation, antioxidant or free radical scavenging or anti-pollution agents, lipolysis stimulating agents, draining or detoxifying agents, anti-inflammatory agents, penetration accelerators and / or anti-irritants, astringent agents,Agents acting on microcirculation, and their mixtures.

10. Non-therapeutic cosmetic or dermocosmetic use of a complex according to any one of claims 1 to 7 or of a composition according to claim 8 or 9, to maintain and / or increase the expression of proteins in the extracellular matrix of healthy skin, preferably said use being a topical cutaneous use.

11. Use according to claim 10, wherein the proteins of the extracellular matrix of healthy skin are fibronectin.

12. Non-therapeutic cosmetic or dermocosmetic use of a complex according to any one of claims 1 to 7 or of a composition according to claim 8 or 9: a) to maintain and / or increase the biomechanical properties of healthy skin, preferably the firmness and / or elasticity of healthy skin, and / or b) for the prevention and / or correction of signs of aging of healthy skin.

13. Non-therapeutic cosmetic or dermocosmetic use of a complex according to any one of claims 1 to 7 or of a composition according to claim 8 or 9, to restore the cutaneous vascular network altered with age in healthy skin.

14. Use of at least one imidazole-modified organic compound of the following general formula (II), or one of its cosmetically or dermocosmetically acceptable salts: H z-. R. W 'TT fo (II) in which: - R1 is -H, -CO2H or -CH2OH, - R2 is: i) either an alkyl chain of the following formula (III): neither) in which: - R3 is -H or -NH2; - R4 is -CO2R5 or -NHR5, with R5 being -H or -COCH3; - n is equal to 1 or 2; ii) let a heterocycle be chosen from: to stabilize an organosilanol of the following general formula (I): (R)x-Si(OH)4 x (I) in which: - the radical R is a linear or branched CrC4 alkyl group, preferably Ci-C2, possibly substituted by at least one hydroxyl group, preferably R is a methyl group, and - x is equal to 1 or 2.